Clinical pediatrics · 2025
Eradication of Methicillin-Resistant Staphylococcus aureus in Cystic Fibrosis.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Guliyeva Aynur, Yilmaz Yegit Cansu, Yanaz Muruvvet, Kalyoncu Mine, Selçuk Balci Merve, Karabulut Seyda, Tastan Gamze, Uzunoglu Burcu, Arslan Hüseyin, Yazan Hakan, Bas Bilgin Gülay, Ayzıt Kılınc Sakallı Ayse, Pinar Ergenekon Almala, Girit Saniye, Cakır Erkan, Gokdemir Yasemin, Erdem Eralp Ela, Karakoc Fazilet, Karadag Bulent
Аннотация
INTRODUCTION: Methicillin-resistant Staphylococcus aureus (MRSA) in cystic fibrosis (CF) impairs lung function and contributes to the progression of the disease. Optimal eradication regimens for new-onset MRSA infections in people with CF (pwCF) remain undefined.
MATERIALS AND METHODS: This prospective, multicenter study evaluated a standardized, step-up MRSA eradication regimen in pwCF with new-onset MRSA infections between 2020 and 2022.
RESULTS: Ninety-one pwCF (52.7% male, median age: 9 years) were included. Our treatment regimen included oral rifampicin and co-trimoxazole or oral rifampicin and fusidic acid. Intravenous teicoplanin treatment was initiated in patients whose clinical condition was unstable. The eradication success rates after 1 year were 82.4%, 92.9%, and 55.6%, respectively. No significant changes in median FEV1% predicted or BMI z-scores were observed between MRSA-eradicated and non-eradicated groups at baseline or 12 months.
CONCLUSION: A standardized step-up MRSA eradication protocol is effective for new-onset MRSA infections in pwCF. Randomized controlled trials are needed to confirm these findings.
MATERIALS AND METHODS: This prospective, multicenter study evaluated a standardized, step-up MRSA eradication regimen in pwCF with new-onset MRSA infections between 2020 and 2022.
RESULTS: Ninety-one pwCF (52.7% male, median age: 9 years) were included. Our treatment regimen included oral rifampicin and co-trimoxazole or oral rifampicin and fusidic acid. Intravenous teicoplanin treatment was initiated in patients whose clinical condition was unstable. The eradication success rates after 1 year were 82.4%, 92.9%, and 55.6%, respectively. No significant changes in median FEV1% predicted or BMI z-scores were observed between MRSA-eradicated and non-eradicated groups at baseline or 12 months.
CONCLUSION: A standardized step-up MRSA eradication protocol is effective for new-onset MRSA infections in pwCF. Randomized controlled trials are needed to confirm these findings.